Recent Company News

• 02:58 AM ET Aug 26, 2026
  

  CSL intends to launch up to A$1.15B on-market buyback, to run between 10-Sep-26 and 30-Jun-27 (A$172.44, 0.00)

• 04:36 PM ET Aug 20, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:27 AM ET Aug 18, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:40 PM ET Aug 17, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 09:04 PM ET Aug 18, 2026
  

  Street Takeaways - CSL FY Earnings (A$165.23, +7.41)

• 02:16 PM ET Aug 18, 2026
  

  CSL upgraded to overweight from neutral at Jarden (A$157.82, 0.00)

• 06:09 AM ET Aug 18, 2026
  

  Haemonetics enters supply agreement with CSL Plasma for company's NexSys PCS devices w/ Persona PLUS tech in the US; maintains FY27 guidance - 8-K ($90.27, 0.00)

• 01:29 AM ET Aug 18, 2026
  

  Quick Take: CSL +18% post results; Immunoglobulin & albumin outperformance provided positive surprise uplift (A$158.79, +24.19)